UPDATE: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70%
June 03, 2014 at 08:33 AM EDT
Gilead Sciences, Inc. (NASDAQ: GILD) today announced updated interim results of a Phase 2 study (Study 102) evaluating GS-9973, its ...